You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of Zika virus therapeutics using a replicon assay

    SBC: MICROBIOTIX, INC.            Topic: R

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family of small positive strand RNA viruses that includes Dengue virusDENVWest Nile virusWNVYellow fever virusYFVand hepatitis C virusHCVZIKV is transmitted to humans by mosquitoes of the Aedes genusFor the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension

    SBC: Arcus-Med LLC            Topic: NHLBI

    Pulmonary hypertensionPHis a disease affecting approximatelyof the general population that is characterized by abnormally elevated mean pulmonary artery pressuremPAPand pulmonary vascular resistancePVRIf left untreatedPH can ultimately lead to right heart failure and deathCurrent diagnostic approaches utilize invasive right heart catheterizationRHCto measure mPAP and PVREarly detection of PH leads ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: Adecto Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A novel drug detection assay using fluorescent biosensor technology

    SBC: GLSynthesis Inc.            Topic: 300

    DESCRIPTION provided by applicant This phase project has as its overall objectives to design engineer optimize and implement a novel genetically encoded fluorescent drug sensor FDS based on F rster Resonance Energy Transfer FRET by exploiting conformational rearrangements induced by drug interactions with human serum albumin SA SA is uniquely suited for a general drug sensor beca ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

    SBC: Initos Pharmaceuticals LLC            Topic: 999

    DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government